[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609041":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":221,"collaborators":223,"id":227,"slug":228,"hasResults":229,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":229,"sex":235,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":26,"studyType":241,"phases":242,"briefSummary":244,"conditions":245,"keywords":253,"overallStatus":87,"whyStopped":26,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},{"fullName":5,"class":6},"InMode MD Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MORPHEUSV Treatment Arm","ACTIVE_COMPARATOR","Participants in this arm will receive a single session of radiofrequency (RF) treatment using the MORPHEUSV device. The treatment is delivered vaginally using a bipolar RF applicator at a therapeutic energy setting. No anesthesia is required. Participants will be followed for 12 months to evaluate safety and effectiveness.",[13],"Device: Detrusor nerve radiofrequency ablation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham Control Arm","SHAM_COMPARATOR","Participants in this arm will undergo a procedure using a visually identical MORPHEUSV applicator, but without RF energy delivery (sham). The procedure mimics the appearance and duration of the active treatment. Participants will be followed for 12 months. After completing the 6-month follow-up, they may elect to cross over and receive a single session of the active RF treatment.",[19],"Device: Simulated (sham) detrusor nerve radiofrequency ablation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Detrusor nerve radiofrequency ablation","A single, vaginal radiofrequency (RF) treatment. The procedure is performed with a bipolar RF applicator and requires no anesthesia. Delivered in a single session in an outpatient setting.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Simulated (sham) detrusor nerve radiofrequency ablation","A simulated (sham) radiofrequency (RF) treatment, but with no energy delivered. The procedure mimics the appearance, duration, and positioning of the active device, without therapeutic effect.",[15],[32],{"name":33,"affiliation":34,"role":35},"Mickey Karram, MD","Foundation for Female Health Awareness (FFHA)","STUDY_DIRECTOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"FFHA Study Manager","CONTACT","573-300-9185","nicholas@femalehealthawareness.org",[43,65,85,103,132,149,166,183,202],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Stanford Medicine Department of Obstetrics & Gynecology","NOT_YET_RECRUITING","Palo Alto","California","94304","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.14302,37.44188,{"lat":55,"lon":54},[58,62],{"name":59,"role":39,"phone":60,"phoneExt":26,"email":61},"Ijeoma Clinical Research Coordinator II","650-725-0620","ijeomaiw@stanford.edu",{"name":63,"role":64,"phone":26,"phoneExt":26,"email":26},"Eric Sokol, MD","PRINCIPAL_INVESTIGATOR",{"facility":66,"status":45,"city":67,"state":68,"zip":69,"country":49,"countryCode":50,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"MedStar Health Research Institute","Washington D.C.","District of Columbia","20010",{"type":52,"coordinates":71},[72,73],-77.03637,38.89511,{"lat":73,"lon":72},[76,80,82],{"name":77,"role":39,"phone":78,"phoneExt":26,"email":79},"Patricia Senior Clinical Program Manager","202-877-0486","Patricia.L.Moriarty@medstar.net",{"name":81,"role":64,"phone":26,"phoneExt":26,"email":26},"Alexis Dieter, MD",{"name":83,"role":84,"phone":26,"phoneExt":26,"email":26},"Cheryl Iglesia, MD","SUB_INVESTIGATOR",{"facility":86,"status":87,"city":88,"state":89,"zip":90,"country":49,"countryCode":50,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Advanced Specialty Research","RECRUITING","Boise","Idaho","83702",{"type":52,"coordinates":92},[93,94],-116.20345,43.6135,{"lat":94,"lon":93},[97,101],{"name":98,"role":39,"phone":99,"phoneExt":26,"email":100},"Jennifer Poralla","(208)-906-1600","Jennifer@idahoasr.com",{"name":102,"role":64,"phone":26,"phoneExt":26,"email":26},"Bill Laitinen, MD",{"facility":104,"status":45,"city":105,"state":106,"zip":107,"country":49,"countryCode":50,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"University of Chicago Medicine Urogynecology","Chicago","Illinois","60062",{"type":52,"coordinates":109},[110,111],-87.65005,41.85003,{"lat":111,"lon":110},[114,118,120,122,124,126,128,130],{"name":115,"role":39,"phone":116,"phoneExt":26,"email":117},"Rowena Shi","773-795-2731","jinxuan.shi@bsd.uchicago.edu",{"name":119,"role":64,"phone":26,"phoneExt":26,"email":26},"Kimberly Kenton, MD",{"name":121,"role":84,"phone":26,"phoneExt":26,"email":26},"Sarah Collins, MD",{"name":123,"role":84,"phone":26,"phoneExt":26,"email":26},"Margaret Mueller, MD",{"name":125,"role":84,"phone":26,"phoneExt":26,"email":26},"Christina Lewicky-Gaupp, MD",{"name":127,"role":84,"phone":26,"phoneExt":26,"email":26},"Juraj Letko, MD",{"name":129,"role":84,"phone":26,"phoneExt":26,"email":26},"Douglas Russo, MD",{"name":131,"role":84,"phone":26,"phoneExt":26,"email":26},"Iris Burgard, MD",{"facility":133,"status":87,"city":134,"state":135,"zip":136,"country":49,"countryCode":50,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Cypress Medical Research Center","Wichita","Kansas","67226",{"type":52,"coordinates":138},[139,140],-97.33754,37.69224,{"lat":140,"lon":139},[143,147],{"name":144,"role":39,"phone":145,"phoneExt":26,"email":146},"Addie Hayes","316-369-0515","addiehayes@cypressmrc.com",{"name":148,"role":64,"phone":26,"phoneExt":26,"email":26},"Kevin Miller, MD",{"facility":150,"status":87,"city":151,"state":152,"zip":153,"country":49,"countryCode":50,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Bay State Clinical Trials","Watertown","Massachusetts","02472",{"type":52,"coordinates":155},[156,157],-71.18283,42.37093,{"lat":157,"lon":156},[160,164],{"name":161,"role":39,"phone":162,"phoneExt":26,"email":163},"Alexia DeOliveira","617-923-0328","deoliveira415@gmail.com",{"name":165,"role":64,"phone":26,"phoneExt":26,"email":26},"Henry Mitcheson, MD",{"facility":167,"status":87,"city":168,"state":169,"zip":170,"country":49,"countryCode":50,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Urology Center, P.C.","Omaha","Nebraska","68114",{"type":52,"coordinates":172},[173,174],-95.94043,41.25626,{"lat":174,"lon":173},[177,181],{"name":178,"role":39,"phone":179,"phoneExt":26,"email":180},"Amy Nelson","402-399-7894","anelson@adultpediatricuro.com",{"name":182,"role":64,"phone":26,"phoneExt":26,"email":26},"Emily Kean-Puccioni, MD",{"facility":184,"status":45,"city":185,"state":186,"zip":187,"country":49,"countryCode":50,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"UNLV Kirk Kerkorian School of Medicine Department of Gynecologic Surgery & Obstetrics","Las Vegas","Nevada","89154",{"type":52,"coordinates":189},[190,191],-115.13722,36.17497,{"lat":191,"lon":190},[194,198,200],{"name":195,"role":39,"phone":196,"phoneExt":26,"email":197},"Yamrot Bekele","702-895-4923","yamrot.bekele@unlv.edu",{"name":199,"role":64,"phone":26,"phoneExt":26,"email":26},"Yarini Quezada, MD",{"name":201,"role":84,"phone":26,"phoneExt":26,"email":26},"Nadia Gomez, MD",{"facility":203,"status":87,"city":204,"state":205,"zip":206,"country":49,"countryCode":50,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Atrium Health Wake Forest Female Pelvic Health Division","Winston-Salem","North Carolina","27103",{"type":52,"coordinates":208},[209,210],-80.24422,36.09986,{"lat":210,"lon":209},[213,217,219],{"name":214,"role":39,"phone":215,"phoneExt":26,"email":216},"Sachin Vyas","336-713-4098","svyas@wakehealth.edu",{"name":218,"role":84,"phone":26,"phoneExt":26,"email":26},"Catherine Matthews, MD",{"name":220,"role":64,"phone":26,"phoneExt":26,"email":26},"Amr Sherif El Haraki, MD",{"type":222,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[224],{"name":225,"class":226},"Foundation for Female Health Awareness","OTHER","100609041","detrusor-nerve-radiofrequency-ablation-for-overactive-bladder-in-women-100609041",false,"NCT07209397","Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women","A Randomized, Prospective, Multicenter, Double-Blind, Sham-Controlled Study to Assess the MORPHEUSV Radiofrequency (RF) Device in the Treatment of Female Patients With Idiopathic Overactive Bladder (OAB) With Urge Incontinence and\u002For Urge-Predominant Mixed Incontinence","DENARA","INCLUSION CRITERIA:\n\n* Female, aged 22 to 80 years inclusive at the time of consent.\n* History of idiopathic overactive bladder (OAB) symptoms for ≥6 months.\n* At least 7 episodes of urge urinary incontinence (UUI) over 3 days, as recorded in a 3-day bladder diary during screening.\n* Urge-predominant incontinence, defined as greater number of UUI episodes than stress urinary incontinence (SUI) episodes during screening.\n* Willing and able to complete the 3-day bladder diary.\n* Willing to discontinue OAB medications (e.g., anticholinergics, beta-3 agonists) at least 2 weeks prior to baseline treatment visit, if currently taking such medications.\n* Willing to use a reliable method of contraception during the study period, if of childbearing potential and sexually active.\n* Negative pregnancy test at screening (if applicable).\n* Willing and able to provide written informed consent and comply with study procedures and follow-up schedule.\n\nEXCLUSION CRITERIA:\n\n* Predominant stress urinary incontinence (SUI) based on bladder diary\n* Currently pregnant, breastfeeding, or planning pregnancy during the study\n* History of neurologic conditions affecting bladder function (e.g., multiple sclerosis, spinal cord injury, Parkinson's disease)\n* Active urinary tract infection (UTI) at screening\n* History of interstitial cystitis, bladder pain syndrome, or chronic pelvic pain\n* Prior or current bladder cancer, pelvic malignancy, or pelvic radiation\n* Pelvic organ prolapse beyond the hymen (POP-Q stage \\> II)\n* Implanted neuromodulation device or prior sacral nerve stimulation\n* Use of bulking agents, Botox, or surgical treatment for incontinence within 12 months\n* Prior pelvic floor RF treatment or laser vaginal rejuvenation\n* Significant pelvic anatomical abnormalities that interfere with treatment\n* Use of investigational drug or device within 30 days before screening\n* Any condition that, in the investigator's opinion, would interfere with safe study participation or data integrity\n* Uncontrolled systemic disease (e.g., uncontrolled diabetes, cardiovascular disease)\n* Inability or unwillingness to comply with study requirements or follow-up","FEMALE","22 Years","80 Years",{"count":239,"type":240},202,"ESTIMATED","INTERVENTIONAL",[243],"NA","The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.",[246,247,248,249,250,251,252],"Overactive Bladder","Overactive Bladder (OAB)","Urge Urinary Incontinence","Mixed Urinary Incontinence (Urge-Predominant)","Mixed Urinary Incontinence","Idiopathic Overactive Bladder With Urinary Incontinence","Idiopathic Overactive Bladder",[254,255,256,257,258,259],"Overactive bladder","Urge urinary incontinence","Mixed urinary incontinence","Female urinary symptoms","urogynecology","Female Urology","2026-01-28",{"date":262,"type":263},"2026-01-30","ACTUAL",{"date":265,"type":263},"2025-11-25",{"date":267,"type":240},"2027-11-30",{"name":5,"class":6},9]